NCT06843473

Brief Summary

This study is investigating how common weight related health problems are in people of different weight categories in India, Pakistan, Philippines, and Vietnam. The purpose of the study is to understand the prevalence of weight related health problems in different weight groups. Participants will continue their normal care and will not get any treatment as part of this study; participants will continue receiving any treatments their doctor has prescribed. The study will last for about 2 years.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,170

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2025

Shorter than P25 for all trials

Geographic Reach
4 countries

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 20, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 25, 2025

Completed
21 days until next milestone

Study Start

First participant enrolled

March 18, 2025

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 11, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 11, 2025

Completed
Last Updated

April 8, 2026

Status Verified

April 1, 2026

Enrollment Period

7 months

First QC Date

February 20, 2025

Last Update Submit

April 7, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Proportion of Weight-Related Complications Across Different Body Mass Index (BMI) Classes

    Percentage (%)

    Upon data collection (Day 1)

Study Arms (1)

Cohort 1

Participants will be assessed for obesity-related complications, including measurement of Body Mass Index (BMI)

Other: No treatment given

Interventions

No treatment given

Cohort 1

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants will be assessed for obesity-related complications, including measurement of Body Mass Index (BMI)

You may qualify if:

  • Informed consent obtained before any study related activities (study-related activities are any procedure related to recording of data according to the protocol).
  • Male or female aged 18 years or older at the time of signing informed consent.
  • Presence of at least one Weight-related complication.

You may not qualify if:

  • Participants less than 18 years of age at the time of signing informed consent.
  • Pregnant women and individuals with recent weight loss due to illness, defined as more than 5 percent (%) weight loss in the past 6 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

AIIMS,Delhi

New Delhi, National Capital Territory of Delhi, 110029, India

Location

National Hospital Lahore

Lahore, 54810, Pakistan

Location

Asian Hospital and Medical Center

Metro Manila, San Juan, 1502, Philippines

Location

Tam Anh TP. Ho Chi Minh General Hospital

Ho Chi Minh City, Tan Binh, 700000, Vietnam

Location

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Clinical Transparency (dept. 2834)

    Novo Nordisk A/S

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 20, 2025

First Posted

February 25, 2025

Study Start

March 18, 2025

Primary Completion

October 11, 2025

Study Completion

October 11, 2025

Last Updated

April 8, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will share

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

More information

Locations